A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

NCT02215616 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

352

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: Laquinimod
DRUG: Placebo

Sponsor

Teva Branded Pharmaceutical Products R&D, Inc.